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Abstract
Background:  Treatment records and follow-up data on 40 patients with primary and metastatic liver
malignancies who underwent a single whole-liver treatment with Y-90 resin microspheres (SIR-Spheres® Sirtex
Medical, Lake Forest, IL) were retrospectively reviewed. The objective of the study was to evaluate the anatomic
and physiologic determinants of radiation dose distribution, and the dose response of tumor and liver toxicity in
patients with liver malignancies who underwent hepatic arterial Y-90 resin microsphere treatment.
Methods: Liver and tumor volume calculations were performed on pre-treatment CT scans. Fractional tumor
and liver flow characteristics and lung shunt fractions were determined using hepatic arterial Tc-99m MAA
imaging. Absorbed dose calculations were performed using the MIRD equations. Liver toxicity was assessed
clinically and by liver function tests. Tumor response to therapy was assessed by CT and/or tumor markers.
Results: Of the 40 patients, 5 had hepatocellular cancer (HCC), and 35 had metastatic liver tumors (15 colorectal
cancer, 10 neuroendocrine tumors, 4 breast cancer, 2 lung cancer, 1 ovarian cancer, 1 endometrial cancer, and
2 unknown primary adenocarcinoma). All patients were treated in a salvage setting with a 3 to 80 week follow-
up (mean: 19 weeks). Tumor volumes ranged from 15.0 to 984.2 cc (mean: 294.9 cc) and tumor to normal liver
uptake ratios ranged from 2.8 to 15.4 (mean: 5.4). Average administered activity was 1.2 GBq (0.4 to 2.4 GBq).
Liver absorbed doses ranged from 0.7 to 99.5 Gy (mean: 17.2 Gy). Tumor absorbed doses ranged from 40.1 to
494.8 Gy (mean: 121.5 Gy). None of the patients had clinical venoocclusive disease or therapy-induced liver
failure. Seven patients (17.5 %) had transient and 7 patients (17.5 %) had persistent LFT abnormalities. There were
27 (67.5%) responders (complete response, partial response, and stable disease). Tumor response correlated
with higher tumor flow ratio as measured by Tc-99m MAA imaging.
Conclusion: Doses up to 99.5 Gy to uninvolved liver are tolerated with no clinical   venoocclusive disease or
liver failure.   The lowest tumor dose producing a detectable response is 40.1 Gy. The utilization of MAA-based
imaging techniques to determine tumor and liver blood flow for clinical treatment planning and the calculation of
administered activity may improve clinical outcomes.
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Background
Yttrium-90 (Y-90) microsphere Selective Internal Radia-
tion Treatment (SIRT), via hepatic arterial administration,
is emerging as a promising treatment modality in the
management of patients with primary and metastatic liver
cancer [1-6]. Selectivity of the procedure is due to the
unique pattern of hepatic arterial flow providing the over-
whelming majority of the tumor blood supply.
The technique was introduced by Ariel [7], who also
reported the first series of successful treatment in patients
with metastatic colorectal cancer (CRC) [8,9]. Ariel's
patients were treated with intra-arterial chemotherapy
and 100 to 150 mCi (3.7 to 5.5 GBq) of Y-90 resin micro-
spheres. The estimated radiation dose to the liver from
100 mCi (3.7GBq) of Y-90 microspheres was 120 to 180
Gy using the Medical Internal Radiation Dosimetry
(MIRD) approach. This treatment modality has been
included in the nuclear medicine literature since its early
applications [10-12]. It has taken a few decades since the
early experience in the nineteen sixties and seventies to
refine the manufacturing technology and administration
techniques of Y-90 microspheres before more structured
studies have been implemented [13-16].
Initial treatment indications were CRC metastases and
hepatocellular carcinoma (HCC), mostly for palliation,
however successful application of microspheres to a vari-
ety of solid tumors is expanding the accepted indications
to include other unresectable metastatic liver tumors [17-
19]. More importantly, down-sizing/down-staging of
hepatic tumors as a bridge to subsequent surgical treat-
ment appears promising. The development of highly
sophisticated techniques of administration has improved
the therapeutic efficacy while minimizing the adverse
effects [20]. Compared to the growing clinical experience
with Y-90 microsphere therapy, anatomic and biologic
factors affecting treatment outcomes are still not clearly
described. In this study we have retrospectively reviewed
the clinical data on patients who underwent whole-liver
SIRT with Y-90 resin microspheres and investigated the
pivotal function of tumor perfusion as quantified by Tc-
99m macroaggregated albumin (MAA) imaging.
Methods
Radiopharmaceutical
All patients were treated with Y-90 Resin microspheres,
SIR-Spheres® (Sirtex Medical Inc, Lake Forest, IL). Resin
microspheres have a relatively consistent diameter within
the range of 35 ± 5 μm. The microspheres are biocompat-
ible but not biodegradable, remaining permanently in the
terminal arterioles of tumor vasculature and at the portal
triad vessels in the normal liver following administration
into the hepatic artery. Yttrium-90 (Y-90) has a half-life of
2.67 days and decays to stable Zirconium-90. It is a pure
beta emitter with an average energy of 0.9337 MeV, and a
mean tissue penetration of 2.5 mm (maximum range: 11
mm). Y-90 is permanently embedded within the resin
structure. No significant amount of Y-90 leaches in the
patient from the resin microspheres. A standard dose of
resin microspheres is 2 GBq, containing approximately 50
million microspheres (range of 40 to 80 million).
Clinical Protocol
Patients with unresectable primary and metastatic liver
disease comprise the study population. All patients had
unresectable disease with histologic confirmation of the
primary cancer.
Patients were evaluated for adequate performance status
(ECOG Performance Status score of less than or equal to
2), bone marrow reserve (granulocytes >1500/μl, platelets
>60,000/μl), and hepatic function (total bilirubin <2.0
mg/dl, ALT/AST, or Alkaline   Phostphatase less than 5
times the upper limit of normal). The patients underwent
a four-phase liver scan (non-contrast, arterial, portal, and
equilibrium phases) for the assessment of liver disease
and the evaluation of extrahepatic metastatic disease. MRI
and FDG-PET imaging were performed as clinically indi-
cated. Disease-specific tumor markers (CEA for CRC
patients, AFP for HCC patients, Serotonin, chromogranin-
A, 5HIAA levels for Carcinoid patients) were obtained in
all patients.
Patients with acceptable liver and renal function under-
went a visceral angiogram to evaluate vascular anatomy.
Branches of the hepatic artery to the GI tract, such as gas-
troduodenal artery and right gastric artery, were some-
times coil-embolized if they posed a threat to reflux down
to the stomach or duodenum At the completion of the
angiogram, the patients were injected with 4 mCi (0.15
GBq) of Tc-99m MAA via the hepatic artery catheter for
planar and SPECT localization imaging. Tc-99m MAA
images were used to determine the lung shunt fraction
(LSF) and to evaluate the extrahepatic GI localization.
Patients with a lung shunting of greater than 20% and any
uncorrectable GI uptake by Tc-99m MAA imaging were
not treated.
The activity to be administered for each patient was deter-
mined by the empiric (Equation 1) or body surface area
(BSA) method (Equation 2).
Empiric method
Tumor volume < 25% total liver volume = 2 GBq
Tumor volume 25–50% total liver volume = 2.5 GBq
Equation 1Journal of Translational Medicine 2007, 5:15 http://www.translational-medicine.com/content/5/1/15
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Tumor volume >50% total liver volume = 3 GBq
Body surface area method
The patients underwent a whole-liver treatment following
the standard administration technique. Follow-up labora-
tory tests included liver function tests (alkaline Phos-
phatase, ALT, AST, and total bilirubin) and tumor
markers. The patients were followed at two and four
weeks post treatment, and then monthly for three
months. The National Cancer Institute's Common Termi-
nology Criteria for Adverse Events (CTCAE v.3) was used
in the grading of the toxicities, and the Response Evalua-
tion Criteria In Solid Tumors (RECIST) criteria was used
for the assessment of tumor response to treatment on CT
images. The final evaluation was performed three months
post treatment. PET scan response criteria were based on
visual non-quantitative interpretation.
Dosimetry
The Medical Internal Radiation Dosimetry (MIRD)
schema was used in the calculation of the absorbed dose
in the tumor, un-involved liver, and lung compartments.
The volume determinations were performed on CT scans
using Pinnacle3 treatment planning software (Philips
Medical), and the activity distribution within individual
compartments was quantified using Tc-99m MAA Planar
and SPECT images. The formulas used to calculate the LSF
and the tumor to normal liver ratio (TLR) are given as
Equations 3 and 4 respectively. LSF calculations are per-
formed using the Planar image set and TLR calculations
are prepared on the SPECT image set (Figure 1).
Lung Shunt Fraction
Tumor to liver ratio
The primary formula used to determine the absorbed dose
in the liver, tumors, and lungs is given as Equation 5. The
tumor and liver masses were equated to volume (tissue
density = 1 g/cc), and the lung masses were related with
volume by multiplying by the assumed lung density of 0.3
g/cc. The fractional uptake is defined as the fraction of the
administered activity expected to be deposited within the
compartment studied (tumors. normal liver tissue, or the
lungs). The lung shunt fraction was used as the fractional
uptake for the lungs. The MIRD equations used in this
study were described in detail elsewhere [21].
Statistical Methods
Statistical analysis was performed to determine the corre-
lation between the parameters studied using SAS Version
9 (Cary, NC). Fisher's Exact Test was used to test associa-
tion between two categorical variables, ANOVA was used
to test association between a categorical variable and a
continuous variable, and linear regression was used to test
association between two continuous variables.
Results
Patients and disease characteristics
Forty patients (23 men, 17 women, ages between 31 and
81) received whole liver selective internal radiation treat-
ment. Diagnoses were CRC in 15, HCC in 5, and neuroen-
docrine tumors (NET) in 10 patients. Ten patients had
metastatic liver disease from various other malignancies
including lung and breast cancers. All patients were
treated in a salvage setting with no further medical or sur-
gical treatment options. Table 1 details the patient and
disease characteristics.
The mean tumor volume was 294.9 ± 284.4 cc (range:
15.0 to 984.2 cc). The mean liver volume was 1662.7 ±
639.0 cc (range: 898.7 to 3982.0 cc). The mean percent
tumor involvement was 14% ± 12% (range: 1% to 48%).
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Single-Photon Emission Computed Tomography (SPECT)  image from a Tc-99m MAA scan used to calculate the TLR Figure 1
Single-Photon Emission Computed Tomography (SPECT) 
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The mean TLR by Tc-99m MAA was 6.1 ± 2.8 (range: 2.8
to 15.4). The mean lung shunt fraction was 3.3% ± 2.8%
(range 0.8% to 14%). There was no difference between
the anatomic and functional findings among different dis-
ease types (Table 2).
TLR and LSF values did not correlate with tumor volume,
liver volume, and percent tumor involvement. The TLR
and LSF values were not significantly different amongst
the disease types (Table 3).
Tumor and liver absorbed dose correlates
Administered activities for the Y-90 resin microspheres
range from 0.4 to 2.4 GBq (mean: 1.2 ± 0.5 GBq). The
mean absorbed doses for the tumor, liver, and lungs were
121.5 ± 85.6, 17.2 ± 18.6, and 2.1 ± 2.3 Gy respectively.
No linear relationship was found between the adminis-
tered activity and tumor absorbed dose. However, the
liver absorbed dose increased with administered activity.
Figure 2 demonstrates the administered activity-absorbed
dose relationships for tumor (A) and liver (B). Table 4
summarizes the correlations between tumor and liver
dose with anatomic/functional findings and administered
activity.  The TLR had a linear relationship with the tumor
absorbed dose with an equation   of y= 15.02x + 29.06
and an R-squared of 0.24. Figure 3 demonstrates the TLR-
absorbed dose relationship.  
Tumor and liver response correlates
The absorbed doses delivered to the tumors ranged from
40.1 Gy to 494.8 Gy (mean: 121.5 ± 85.6 Gy). Partial
response or disease stabilization was observed in 27
(67.5%) patients. Median tumor absorbed doses for
responders and non-responders were 107.8 Gy and 76.9
Gy respectively. The lowest tumor absorbed dose produc-
ing a detectable response was 40 Gy.  The tumor response
rates for patients with CRC, HCC, and NET were 47%,
80%, and 100% respectively. Tumor response by dose is
shown in Table 5 and tumor response by disease is
detailed in Table 6. 
Liver absorbed doses ranged from 0.7 Gy to 99.5 Gy
(mean: 17.2 ± 18.6 Gy). Seven patients (17.5 %) had tran-
sient, and 7 patients (17.5 %) had persistent liver function
test (LFT) abnormalities. The appearance of LFT abnor-
malities did not correlate with diagnosis, liver volume, or
liver dose. None of the patients had clinical radiation hep-
atitis or therapy-induced liver failure. The liver response/
toxicity data is shown in Table 7.
Discussion
Radiation-associated hepatic injury has been the major
hindrance in the treatment of liver malignancies using
external beam radiotherapy. The incidence of potentially
lethal radiation hepatitis is approximately 75% with doses
in excess of 40 Gy to the whole liver using conventional
external beam radiation treatment (RT) [22]. Therefore
the tumoricidal dose is difficult to achieve using external
beam RT.  Conformal and stereotactic radiation therapy
Table 1: Patient and disease characteristics
Age
31–80 (Mean: 59)
Sex
17 female 23 male
Disease n
Colorectal cancer 15
Hepatocellular carcinoma 5
Neuroendocrine tumors 10
Breast cancer 4
Lung cancer 2
Endometrial cancer 1
Ovarian cancer 1
Unknown primary 2
Table 2: Anatomic and functional findings according to disease type
Numbers in parentheses specify the range
Anatomic and functional findings Disease type
HCC CRC NET All
374.6 175.05 460.1 294.93
Tumor volume (cc) (33.2–857.8) (15.7–719.9) (15.0–984.2) (15.0–984.2)
1592.5 2250.3 1678.5 1662.7
Liver volume (cc) (1125.9–3982.0) (898.7–2194.0) (906.0–3331.8) (898.7–3982.0)
13.2% 8.8% 20.8% 14%
Tumor involvement (%) (2.9–30.9%) (0.9–33.6%) (1.1–48.5%) (0.9–48.5%)
7.0 6.8 5.9 6.1
Tumor to normal liver ratio (3.9–9.2) (2.9–15.4) (3.5–11.1) (2.8–15.4)
2.1% 4.3% 2.9% 3.3%
Lung shunt fraction (0.9–3.3%) (1.1–13.6%) (0.8–8.8%) (0.8–13.6%)Journal of Translational Medicine 2007, 5:15 http://www.translational-medicine.com/content/5/1/15
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techniques can be used to deliver much higher radiation
doses for treatment of focal disease[23]; however, since
hepatic metastases are most often multifocal and irregular
in shape and may replace large parts of the liver volume,
only a minority of patients are optimal candidates for
such therapies.
The therapeutic ratio with SIRT, compared to external
beam RT, is significantly improved, and the tumor
absorbed doses from SIRT are typically 4 to 6 times higher
than those to the liver tissue [24]. The tumoricidal dose
with SIRT has not been clearly determined, and the liver
absorbed doses, clinically judged to be tolerated well, are
mostly based on coarse dosimetric estimates. Although
the clinical efficacy of SIRT in producing objective
responses, with a relatively wide margin of safety, has
been clearly demonstrated in numerous studies [4,5,13-
16,25], a safe liver absorbed dose has not been defined.
The liver absorbed doses reported in the literature range
from 34 to 181 Gy [25-29]. This variability is primarily
due to the differences in the dosimetric methodologies
adopted. It is further accentuated with the heterogeneity
in the available retrospective data that involves different
disease types with different underlying functional liver
abnormalities and previous treatments.
Microspheres are deposited in the liver as a number of dis-
crete clusters, rather than point sources that are homoge-
neously distributed throughout the tumor. This irregular
but non-random clustering of microspheres produces a
highly heterogeneous radiation dose distribution pattern.
Microsphere distribution in and around tumors is com-
plex. Microspheres lodge preferentially in the growing rim
of the tumor. The central portion of lesions, often times
hypoperfused and sometimes necrotic, receive a much
smaller number of microspheres, if any. The variability in
the dose distribution with Y-90 microsphere treatment
has been emphasized in a number of studies [24,30,31].
The uncertainty of dose deposition is very unsettling for
both conventional brachytherapy, and the MIRD method-
ology of nuclear medicine.
Microspheres distribute within tumor and liver compart-
ments. The differential deposition of microspheres favor-
ing the tumor compartment is expressed as the TLR. The
"selectivity" of the Y-90 microsphere treatment is deter-
mined primarily by the TLR, the biologic determinants of
which include the angiogenic potential and pattern of the
tumors, and the growth rate-dependent tumor perfusion.
The TLR, in our study, did not correlate with tumor vol-
ume, liver volume, or percent tumor involvement. There
was no correlation between the TLR and tumor type
within the observed range of 2.8 to 15.4. The TLR had a
linear relationship with the tumor absorbed dose with an
equation of y = 15.02x + 29.06 and an R-squared of 0.24.
Table 3: TLR and LSF correlations with anatomic findings
TLR LSF
Tumor volume p = 0.27 p = 0.22
Liver volume p = 0.37 p = 0.22
Tumor involvement (%) p = 0.55 p = 0.38
Disease type p = 0.24 p = 0.32
Correlation between the tumor and liver absorbed doses and the administered activity Figure 2
Correlation between the tumor and liver absorbed doses and the administered activity. There is a linear relationship between 
the administered activity and the liver absorbed dose with an equation of y = 26.80x - 15.55 and an R-squared value of 0.46. No 
such relationship is seen between the administered activity and the tumor absorbed dose.Journal of Translational Medicine 2007, 5:15 http://www.translational-medicine.com/content/5/1/15
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Currently, MAA scans are performed routinely prior to
SIRT for the assessment of lung shunting and extrahepatic
uptake. This is widely recognized to be important for min-
imizing the risk of potentially debilitating adverse events
such as radiation pneumonitis or radiation gastritis/duo-
denitis. MAA particles are of similar size and density as
resin microspheres (MAA   particles have diameters in the
range 15 to 30 microns and a density of 1.3   g/cc and SIR-
Sphere microspheres have diameters of 35 ± 5 microns
and a density of 1.6 g/cc). Although the number of parti-
cles for MAA and resin microsphere suspensions (in a unit
of administered volume) is significantly different (micro-
spheres are concentrated 10-fold) and the potential effect
of this difference on the distribution kinetics has never
been studied, it is reasonable to conclude that the two par-
ticles will be distributed similarly within the liver and the
tumor compartments. Several studies have demonstrated
the value of the MAA scan in planning of a successful SIRT
[32-34]. The role of the MAA scan was challenged by
Dhabuwala et al. in a recent paper which aimed to deter-
mine whether the pattern or degree of MAA uptake by
liver tumors after hepatic arterial injection might be a pre-
dictor of response to subsequent SIRT with resin micro-
spheres [35]. The authors were not able to demonstrate a
correlation between MAA uptake in the CRC liver metas-
tases prior to SIRT and response to the treatment deter-
mined by CEA, CT, or survival time. However, this study
suffered serious methodological problems. The MAA was
injected 1 to 2 hours prior to the SIRT. The SIRT was
administered to the patients after injecting angiotensin 2
into the hepatic artery, whereas the MAA perfusion scans
were performed without angiotensin 2. The effects of the
incomplete clearance of MAA on subsequent Y-90 micro-
sphere injection and the application of angiotensin 2
pharmacological manipulation to the therapy session but
not to the MAA administration confounded the results.
The use of simple planar images for the quantitative ele-
ment of the study brought a significant degree of impreci-
sion to the measurement of the MAA uptake as well.
The theory of SIRT is based on a favorable TLR. MAA imag-
ing is a good measure of TLR, despite its significant tech-
nical limitations. A high resolution SPECT acquisition
and processing is essential in MAA image interpretation
and quantitation. The avascular core of the lesions needs
to be excluded from the activity calculation during quan-
titative image processing for improved accuracy. The MAA
directly shows the site and the amount of anticipated radi-
ation dose deposition. The vascularity of different tumor
types has been studied extensively. A vascularity grade as
assessed by an arteriogram may not necessarily predict the
TLR measured from an MAA scan. The wide range of TLR
for many types of tumors also indicate that, based on the
histologic type, the targeting efficiency of Y-90 micro-
spheres (or MAA) may not be correctly estimated. The
individual TLR is determined by the stage and the pattern
of angiogenesis, and also by synchronous events of apop-
tosis and necrosis. There are no scientific grounds for pre-
cluding any particular type of liver malignancy for SIRT,
nor is there a credible way of predicting favorable tumor
targeting without MAA imaging. The correlation between
the TLR and clinical outcome may be more difficult to
establish as the clinical response is determined by many
other factors. The radiosensitivity of the tumor (intrinsic
or microenviromental), therapeutic threshold, and the
tumor growth rate-to-necrosis/apoptosis ratio could play
significant role in producing objective tumor responses.
The second important observation in our study was
related to the relationships between tumor and liver
There is a linear relationship between TLR and tumor  absorbed dose with an equation of y = 15.02x.+29.06 and an  R-squared of 0.24 Figure 3
There is a linear relationship between TLR and tumor 
absorbed dose with an equation of y = 15.02x.+29.06 and an 
R-squared of 0.24. The TLR is determined using Tc-99m 
MAA SPECT imaging.
Table 4: Tumor and liver dose correlations with anatomic/functional findings and administered activity
Tumor dose (Gy) Liver dose (Gy)
Tumor involvement (%) p = 0.003* p < 0.0001*
Tumor to liver ratio p < 0.0001* p = 0.47
Administered activity p > 0.99 p < 0.0001*
Disease type p = 0.65 p = 0.20Journal of Translational Medicine 2007, 5:15 http://www.translational-medicine.com/content/5/1/15
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absorbed doses and administered activity. The tumor
absorbed dose did not correlate with the administered
activity. However, there was a linear correlation between
the liver absorbed dose and the administered activity.
The estimation of the tumor absorbed dose with Y-90
microspheres using MIRD macrodosimetry approach is
problematic. The non-uniformity of microsphere distri-
bution is not only a function of irregular tumor angio-
architecture, but also is complicated with flow-bound dis-
tribution physics. Although the total dose delivered to the
tumor compartment can be determined reasonably accu-
rate, the dose deposition pattern in the different zones
within a given tumor mass does challenge the limits of
macrodosimetry. The angiogenic belt at the tumor-nor-
mal tissue boundary has the highest and relatively uni-
form microsphere distribution. A full radiation dose
deposition occurs in this zone while an inner zone
receives an attenuated dose from the far range beta emis-
sion of the former. The radiation deposition within
deeper tumor regions is drastically lower than that at the
periphery.
The inhomogeneity in the distribution of the micro-
spheres in the liver tissue is to a lesser scale when com-
pared to the distribution of microspheres in the tumor.
Radiation dose to healthy liver parenchyma is determined
by the number of microspheres administered, the specific
activity of the microspheres, and the distance between the
microspheres implanted. The liver tissue receiving the
highest dose is that which is immediately surrounding the
tumor. The radiation injury to this area of parenchyma is
more pronounced. There is an abrupt drop in the radia-
tion dose towards the surrounding liver a few millimeters
from the high dose zone around the tumor [31]. The
remainder of the liver receives less radiation than would
be predicted from assuming a homogeneous distribution
of radiation dose throughout the parenchyma. Fox et al.
have demonstrated that almost 90% of the liver tissue
received less than the dose predicted by assuming uniform
distribution, and a third of the tissue received less than
one-third of the predicted dose [24]. This partially
explains the lack of classical clinical radiation hepatitis at
much higher dose levels as estimated by MIRD methodol-
ogy. The linear relationship between administered activity
and liver dose observed in our study indicates that MIRD
estimates could be clinically useful in defining safe liver
dose limits. The application of microdosimetry tech-
niques will improve the reproducibility of the radiation
dose calculations. This clearly requires higher resolution
functional diagnostic imaging.
The third set of observations in our study was related to
the dose response in tumor and liver. Objective tumor
response was seen in more than 50% of all patients. There
was no difference in mean absorbed tumor dose estimates
amongst the disease types. The differences in response
could perhaps be explained by variations in radiosensitiv-
ity. This result could also be partly due to the differences
in the techniques used to assess the treatment response.
FDG-PET response usually is observed before a volume
change is appreciated on CT imaging [36]. Similarly,
tumor markers and/or octreoscan changes might be more
sensitive indices of objective response for NET compared
to CT imaging alone. A concrete conclusion regarding the
differences in objective response amongst disease catego-
ries may not be drawn with a restricted sample size.
There was no classical clinical radiation hepatitis or ther-
apy-induced liver failure at liver absorbed doses up to 99
Gy. In 63% of the patients, there were no significant LFT
changes and in 18%, the initial LFT abnormalities were
improved in 2 to 4 weeks. A grade 1 to 2 rise in LFT values
was not uncommon following treatments associated with
Table 5: Relationship between tumor absorbed dose and tumor response
Tumor response Patients Tumor dose (Gy)
Average Median
Responders 27 120.3 107.8
Non-responders 13 123.9 76.9
Table 6: Tumor response by disease type
Disease Patients Tumor absorbed dose (Gy) Tumor response
Colorectal cancer 15 136.7 (43.4–494.8) 47%
Hepatocellular carcinoma 5 135.2 (57.0–310.0) 80%
Neuroendocrine tumors 10 123.6 (40.1–262.7) 100%
Other 10 89.6 (56.2–208.4) 60%Journal of Translational Medicine 2007, 5:15 http://www.translational-medicine.com/content/5/1/15
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angiographic evidence of stasis at the end of the micro-
sphere administration.
The liver response (toxicity) to radiation appears to be dif-
ferent in SIRT than in external beam RT. This is mainly
due to the lower dose rates maintained by virtue of the
selectivity of Y-90 microsphere treatment. The differences
in the severity and pattern of liver toxicity could be related
to the radio-patho-biologic differences in both tech-
niques. The pathogenesis of radiation damage from exter-
nal beam RT to the liver is dominated by vascular injury
in the centri-lobular region. External beam radiation
causes alterations in the central veins such as eccentric
wall thickening and subsequent obliteration of the lumen
leading to veno-occlusive disease [37]. Radiation from
microspheres, however, is deposited primarily in the por-
tal triads. The relative segregation of the central vein from
the radiation source was suggested to be important in
minimizing the toxicity due to venoocclusive disease [26].
However, the toxicity related to the radiation effects on
the biliary tract and distal portal tributaries should be
approached with due caution.
Conclusion
An analysis of radiation distribution in the tumor and
liver compartments indicated that the tumor absorbed
dose best correlated with tumor-to-liver Tc-99m MAA
uptake ratio supporting the clinical value of quantifica-
tion of activity distribution and dose calculations before
the administration of Y-90 microsphere treatment. The
majority of patients exhibited an objective treatment
response. Liver absorbed doses up to 100 Gy were well tol-
erated with no clinical venoocclusive disease or liver fail-
ure. The lowest tumor dose producing a detectable
response was 40 Gy. The utilization of MAA-based imag-
ing techniques to determine tumor and liver blood flow
for clinical treatment planning and the determination of
administered activity may improve clinical outcomes. The
accuracy of dose estimates will improve parallel to the
improvements in the techniques of image quantitation for
determination of activity distribution.
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